TSO3 (TOS) Given “Buy” Rating at Echelon Wealth Partners

Share on StockTwits

TSO3 (TSE:TOS)‘s stock had its “buy” rating restated by research analysts at Echelon Wealth Partners in a report issued on Wednesday.

A number of other research analysts have also issued reports on TOS. National Bank Financial restated a “sector perform” rating and set a C$1.25 price target on shares of TSO3 in a research note on Thursday, December 20th. Royal Bank of Canada decreased their target price on shares of TSO3 from C$0.90 to C$0.80 and set a “sector perform” rating on the stock in a research report on Thursday, November 8th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company has an average rating of “Hold” and an average target price of C$1.58.

TSE:TOS opened at C$0.64 on Wednesday. TSO3 has a 12-month low of C$0.35 and a 12-month high of C$2.74. The company has a debt-to-equity ratio of 415.90, a quick ratio of 7.26 and a current ratio of 9.07.

TSO3 (TSE:TOS) last released its quarterly earnings results on Tuesday, November 6th. The company reported C($0.03) earnings per share for the quarter, topping the consensus estimate of C($0.05) by C$0.02. The firm had revenue of C$1.02 million during the quarter, compared to the consensus estimate of C$0.65 million. Research analysts anticipate that TSO3 will post -0.08 earnings per share for the current year.

About TSO3

TSO3 Inc engages in the research, development, production, maintenance, sale, and licensing of sterilization processes, related consumable supplies, and accessories for heat and moisture sensitive medical devices worldwide. Its principal product is the STERIZONE VP4 sterilizer, a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide and ozone that is marketed in Canada and the United States.

Featured Story: How dollar cost averaging works

Analyst Recommendations for TSO3 (TSE:TOS)

Receive News & Ratings for TSO3 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TSO3 and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply